エンタシス・セラピューティクス(Entasis Therapeutics 以下エンタシス)社とGARDPが、ファースト・イン・クラス (first-in-class) の淋菌感染症治療薬であるゾリフロダシン (Zoliflodacin)の国際共同第3相臨床試験を開始

[2019年9月30日ジュネーブ(スイス)/ウォルサム(米国マサチューセッツ州)]

ジュネーブ(スイス)/ウォルサム(米国マサチューセッツ州)-9月30日 -本日、薬剤耐性感染症への新規治療薬を開発する非営利組織であるグローバル抗菌薬研究開発パートナーシップ (Global Antibiotic Research & Development Partnership: GARDP)と新規抗菌薬の創薬と開発に重点的に取り組むクリニカル・ステージ(臨床特化型)のバイオ製薬企業であるエンタシス・セラピューティクス社(NASDAQ: ETTX)は共に、ゾリフロダシンの国際共同第3相臨床試験が開始されたことを発表しました。ゾリフロダシンは、合併症のない淋菌感染症への治療薬として開発された新規ファースト・イン・クラス (first-in-class) の経口抗菌薬です。これまでにNew England Journal of Medicine (NEJM)誌で発表された第2相試験の良好な結果に続き、GARDPがすべての資金を提供し、国際第3相試験をサポートする形で、エンタシス社とGARDPが連携して開発の後期段階を完了させます。

GARDP und Entasis Therapeutics leiten globale Phase-III-Studie für Zoliflodacin, ein neuartiges orales Antibiotikum zur Behandlung von Gonorrhoe, ein

[Genf, Schweiz und Waltham, USA – 30 September 2019]

Die gemeinnützige Organisation Global Antibiotic Research and Development Partnership (GARDP), die neue Therapien gegen medikamentenresistente Infektionen entwickelt, und Entasis Therapeutics (NASDAQ: ETTX), ein auf der klinischen Stufe aktives biopharmazeutisches Unternehmen, das sich auf die Entdeckung und Entwicklung neuartiger antibakterieller Produkte konzentriert, gaben heute gemeinsam die Einleitung einer globalen Phase-III-Zulassungsstudie für Zoliflodacin bekannt.

GARDP and Entasis Therapeutics initiate global phase 3 trial of zoliflodacin, a first-in-class oral antibiotic for the treatment of gonorrhoea

[Geneva, Switzerland and Waltham, USA  – 19 August 2019]

The Global Antibiotic Research and Development Partnership (GARDP), a not for profit organisation developing new treatments for drug resistant infections, and Entasis Therapeutics (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today jointly announced the initiation of a global phase 3 pivotal trial of zoliflodacin. Zoliflodacin is a novel, first-in-class oral antibiotic being developed for the treatment of gonorrhoea.

GARPD et Entasis Therapeutics lancent un essai clinique de phase 3 de la zoliflodacine, un nouvel antibiotique pour le traitement de la gonorrhée

[Genève, Suisse et Waltham, Éats-Unis – 23 September 2019]

Le Partenariat mondial sur la recherche-développement en matière d’antibiotiques (GARDP), organisation à but non lucratif qui met au point de nouveaux traitements contre les infections résistantes aux antibiotiques, et Entasis Therapeutics (NASDAQ: ETTX), société biopharmaceutique qui se spécialise dans la découverte et le développement de produits antibactériens novateurs, ont annoncé conjointement aujourd’hui le lancement d’un essai pivot mondial de phase 3 évaluant la zoliflodacine. La zoliflodacine est un antibiotique oral, d’une nouvelle classe, mis au point pour le traitement de la gonorrhée.

GARDP · 엔타시스 테라퓨틱스, 임질 치료용 경구 항생제 혁신신약 졸리플로다신의 글로벌 임상 3상 시험 시작

[9월 30일, 제네바(스위스) · 월섬(미 메사추세츠)]

약제내성 감염병에 대한 신약을 개발하는 비영리 단체 글로벌 항생제 연구개발 파트너십(Global Antibiotic Research and Development Partnership, GARDP), 새로운 항균 제품 발견 및 개발에 중점을 두는 임상 단계 생물약제 전문회사 엔타시스 테라퓨틱스(Entasis Therapeutics, 나스닥 상장: ETTX)는 졸리플로다신을 검증하는 중대한 글로벌 임상 3상 시험에 첫 환자군을 등록해 시험을 시작한다고 오늘 발표했다.

2nd Antimicrobial Chemotherapy Conference

21 January 2020
London, England

Join us at the World Health Summit to learn how GARDP’s ‘5 BY 25’ goal will accelerate the development and delivery of five new and improved treatments to address antibiotic-resistant
infections that pose the greatest threat to health and development.

GARDP and FIND part of ARC Research Hub on AMR

[Geneva – 19 August 2019] 

GARDP and FIND welcome the Australian Minister for Education’s announcement of $5m to establish an Australian Research Council (ARC) Research Hub to Combat Antimicrobial Resistance, which will be led by the Kirby Institute.

Uniting against antibiotic resistance: 5 BY 25

28 October 2019
Berlin, Germany

Join us at the World Health Summit to learn how GARDP’s ‘5 BY 25’ goal will accelerate the development and delivery of five new and improved treatments to address antibiotic-resistant
infections that pose the greatest threat to health and development.

GARDP announces ‘5 BY 25’ goal in response to the growing burden of antibiotic resistant infections

[Geneva – 26 June 2019] 

GARDP calls upon the global community to work with it to develop and deliver 5 new treatments by 2025 to address the most urgent public health needs

Today GARDP announces its ‘5 BY 25’ goal to deliver five new treatments in response to the growing global threat of antimicrobial resistance (AMR). GARDP’s five treatments will focus on the priority bacterial pathogens identified by the World Health Organization (WHO).